Dermata Therapeutics Enters Material Definitive Agreement

TL;DR

DRMA signed a big deal, details TBD.

AI Summary

Dermata Therapeutics, Inc. announced on June 7, 2024, that it entered into a Material Definitive Agreement. The filing does not provide specific details on the agreement or any associated financial figures.

Why It Matters

This filing indicates a significant new contract or partnership for Dermata Therapeutics, which could impact its future operations and financial performance.

Risk Assessment

Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.

Key Players & Entities

• Dermata Therapeutics, Inc. (company) — Registrant
• June 7, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share DRMA The Nasdaq Capital M
• $1,157,761 — ATM Prospectus Supplement is currently $1,157,761 which is based on the limitations of Ge
• $70,000 — TM Agreement in an amount not to exceed $70,000 in the aggregate, in addition to $5,000
• $5,000 — 70,000 in the aggregate, in addition to $5,000 per annual due diligence session update
• $2,500 — ompany's Annual Report on Form 10-K and $2,500 per quarterly due diligence update sess

Filing Documents

• drma_8k.htm (8-K) — 36KB
• drma_ex11.htm (EX-1.1) — 206KB
• drma_ex51.htm (EX-5.1) — 10KB
• drma_ex51img3.jpg (GRAPHIC) — 5KB
• drma_ex51img4.jpg (GRAPHIC) — 7KB
• 0001654954-24-007532.txt ( ) — 464KB
• drma-20240607.xsd (EX-101.SCH) — 6KB
• drma-20240607_lab.xml (EX-101.LAB) — 16KB
• drma-20240607_cal.xml (EX-101.CAL) — 1KB
• drma-20240607_pre.xml (EX-101.PRE) — 12KB
• drma-20240607_def.xml (EX-101.DEF) — 4KB
• drma_8k_htm.xml (XML) — 6KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On June 7, 2024, Dermata Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an At The Market Offering Agreement (the "ATM Agreement") with H.C. Wainwright & Co., LLC (the "Sales Agent" or "Wainwright") providing for the sale by the Company of its shares of common stock, par value $0.0001 per share (the "Common Stock"), from time to time, through the Sales Agent, with certain limitations on the amount of Common Stock that may be offered and sold by the Company as set forth in the ATM Agreement (the "Offering"). Offers and sales of shares of Common Stock by the Company, if any, under the ATM Agreement, will be made through a prospectus supplement, dated June 7, 2024, and an accompanying base prospectus, dated November 25, 2022, contained therein (the "ATM Prospectus Supplement"), which together form a part of the Company's shelf registration statement on Form S-3 (File No. 333-268383), initially filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") on November 15, 2022 (the "Registration Statement") and declared effective by the SEC on November 25, 2022. The aggregate market value of the shares of Common Stock eligible for sale under the ATM Prospectus Supplement is currently $1,157,761 which is based on the limitations of General Instruction I.B.6 of Form S-3. Pursuant to the ATM Agreement, the Company will set the parameters for the sale of shares of Common Stock, including the number of shares to be issued, the time period during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the ATM Agreement, the Sales Agent may sell the shares by methods deemed to be an "at the market offering" as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended (the "Securities Act"), including w

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 ATM Agreement, dated June 7, 2024, by and between Dermata Therapeutics, Inc. and H.C. Wainwright & Co., LLC. 5.1 Opinion of Lowenstein Sandler LLP. 23.1 Consent of Lowenstein Sandler LLP (contained in Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 3

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 7, 2024 DERMATA THERAPEUTICS, INC. By: /s/ Gerald T. Proehl Gerald T. Proehl President, Chairman and Chief Executive Officer 4

View Full Filing

View this 8-K filing on SEC EDGAR